WHAT IS CLAIMED IS:

1. A method for determining whether a subject has or is predisposed for a mood disorder, the method comprising the steps of:

(i) obtaining a biological sample from a subject;

(ii) contacting the sample with a reagent that selectively associates with a polynucleotide or polypeptide encoded by a nucleic acid that hybridizes under stringent conditions to a nucleotide sequence of Table 2, 3, or 4; and

(iii) detecting the level of reagent that selectively associates with the sample, thereby determining whether the subject has or is predisposed for a mood disorder.

2. The method of claim 1, wherein the reagent is an antibody.

3. The method of claim 1, wherein the reagent is a nucleic acid.

4. The method of claim 1, wherein the reagent associates with a polynucleotide.

5. The method of claim 1, wherein the regent associates with a polypeptide.

6. The method of claim 1, wherein the level of reagent that associates with the sample is different from a level associated with humans without a mood disorder.

7. The method of claim 1, wherein the biological sample is obtained from amniotic fluid.

8. The method of claim 1, wherein the mood disorder is selected from the group consisting of bipolar disorder I, bipolar disorder II, and major depression disorder.

9. The method of claim 6, wherein the level of reagent that associates with the sample is higher than a level associated with humans without a mood disorder.

10. The method of claim 6, wherein the level of reagent that associates with the sample is lower than a level associated with humans without a mood disorder.

11. A method of identifying a compound for treatment or prevention of a mood disorder, the method comprising the steps of:

(i) contacting the compound with a polypeptide, the polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a nucleic acid sequence comprising a nucleotide sequence of Table 2, 3, or 4; and

(ii) determining the functional effect of the compound upon the polypeptide, thereby identifying a compound for treatment or prevention of a mood disorder.

12. The method of claim 11, wherein the contacting step is performed *in vitro*.

13. The method of claim 11, wherein the polypeptide is expressed in a cell and the cell is contacted with the compound.

14. The method of claim 11, the mood disorder is selected from the group consisting of bipolar disorder I, bipolar disorder II, and major depression disorder.

15. The method of claim 11, further comprising administering the compound to an animal and determining the effect on the animal.

16. The method of claim 15, wherein the determining step comprises testing the animal's mental function.

17. A method of identifying a compound for treatment of a mood disorder in a subject, the method comprising the steps of:

(i) contacting the compound to a cell, the cell comprising a polynucleotide that hybridizes under stringent conditions to a nucleotide sequence of Table 2, 3, or 4; and

(ii) selecting a compound that modulates expression of the polynucleotide, thereby identifying a compound for treatment of a mood disorder.

18. The method of claim 17, wherein the expression of the polynucleotide is enhanced.

19. The method of claim 17, wherein the expression of the polynucleotide is decreased.

20. The method of claim 17, further comprising administering the compound to an animal and determining the effect on the animal.

21. The method of claim 20, wherein the determining step comprises testing the animal's mental function.

22. The method of claim 17, wherein the mood disorder is selected from the group consisting of bipolar disorder I, bipolar disorder II, and major depression disorder.

23. A method of treating a mood disorder in a subject, the method comprising the step of administering to the subject a therapeutically effective amount of a compound identified using the method of claim 11 or claim 17.

24. The method of claim 23, wherein the mood disorder is selected from the group consisting of bipolar disorder I, bipolar disorder II, and major depression disorder.

25. The method of claim 23, wherein the compound is a small organic molecule.

26. A method of treating a mood disorder in a subject, the method comprising the step of administering to the subject a therapeutically effective amount of a polypeptide, the polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a nucleotide sequence of Table 2, 3, or 4.

27. The method of claim 26, wherein the mood disorder is selected from the group consisting of bipolar disorder I, bipolar disorder II, and major depression disorder.

28. A method of treating a mood disorder in a subject, the method comprising the step of administering to the subject a therapeutically effective amount of a nucleic acid, wherein the nucleic acid hybridizes under stringent conditions to a nucleotide sequence of Table 2, 3, or 4.

29. The method of claim 28, wherein the mood disorder is selected from the group consisting of bipolar disorder I, bipolar disorder II, and major depression disorder.